HIV-associated Guillain-Barré Syndrome is a well-documented phenomenon, typically occurring at seroconversion. GBS may result in functional impairment treated with a combination of medications, plasmapheresis, and rehabilitation. The quantified functional recovery of HIV-associated GBS with or without HIV treatment is not welldescribed. Utilizing serial FIM scoring, we describe a patient's recovery from HIVassociated GBS after treatment with IVIg and acute inpatient rehabilitation without HIV treatment.
Introduction
Standard Guillain-Barré Syndrome (sGBS) is an autoimmune disorder characterized by sudden onset of weakness with evidence of demyelination through electrodiagnosis. 1 This condition often requires pharmacological and/or plasmapheresis treatment. After treatment, 40% of sGBS patients require inpatient rehabilitation. 2 The most rapid improvement is the first 6 months. 3 sGBS recovers during the first year of onset, motor improvements at 18 months, but motor and sensory impairments are detectable in more than 50% of patients at two years. 4 Functional Independence Measure (FIM TM ) is a proven tool to monitor rehabilitation progress of sGBS.
5
There are several peripheral neuropathies associated with HIV. 6 HIV-associated GBS (hGBS) is well documented. 7, 8, 9 which may occur during the entire course of the disease, but typically occurs at seroconversion, 10, 11, 12 but may Quinn's states "neurological impairment [from HIV] is generally self-limited; most patients become asymptomatic in 1 to 4 weeks, although persistent neurologic deficits have been described." 13 Recent literature describes prolonged recovery of HIV-related chronic neurologic conditions. 10 Verma speculates that the clinical course and response to pharmacologic treatment for GBS in HIV-seropositive and seronegative patients is similar 14 , but the functional recovery of hGBS with or without HIV treatment is not well described. We describe a case of hGBS without HIV treatment with subacute recovery. Functional Independent Measure (FIM TM ) scores showed functional deficit requiring moderate assistance for self care, minimal assistance for sphincter control, and dependence for ambulation (Table 1) . She initially made gains but then experienced progressive weakness and decline in many functional domains (Table 1) .
Work-up included a second electrodiagnostic study approximately 1 month after initial study, revealing more evidence of a demyelinating polyneuropathy (Table 2) Rehabilitation was reinitiated without further pharmacological treatment for GBS or HIV.
Due to concern for compliance, infectious disease consultant did not treat HIV. One month after readmission she displayed functional improvement at supervision for most self care domains, independence with sphincter control, modified independent for mobility at a wheel chair level (Table 1) . Her exam on discharge revealed symmetric 1+ reflexes with sensation intact to light touch and pinprick. Manual muscle testing revealed 4+-5/5 strength in all muscle groups. Three months after discharge and five months after onset of hGBS, she had complete functional recovery; independent in all FIM TM domains including ambulation without assistive device (see Table 1 ). She was lost to further follow-up.
Discussion
We present a case of GBS occurring as the first manifestation of HIV infection and her functional recovery after IVIG and inpatient rehabilitation which suggests that hGBS patients may make full subacute recovery without the initiation of HAART therapy. To our knowledge, there are no reports of acute seroconverted hGBS rehabilitation recovery without HIV treatment. This may add to the controversy in the literature regarding hGBS treatment with HAART with both relapse 16 upon discontinuation or cause due to drug side effect or of HAART or potentially cause via immune reconstitution syndrome. 17 Neurologic impairment related to HIV are recognized have prolonged recovery at best. 13, 18 Our case presents hGBS taking 5 months full functional recovery. This is timely as compared to the described recovery of sGBS and confirms Verma's speculation. 14 Limitations of this manuscript include the use of FIM TM scoring to quantify functional recovery, as there are other tools to evaluate recovery of GBS patients. 19 Additionally, she was lost to follow-up to monitor for function over a longer period of time.
Conclusion
We present a case of Guillain-Barré Syndrome as the initial clinical manifestation of HIV infection. With standard GBS treatment, without HIV treatment, the patient made similar functional recovery, quantified by FIM TM scoring, that is described for sGBS. Further research is needed on the recovery of HIV-associated GBS with various treatment strategies so physicians can better prognosticate functional recovery.
